**3. Current Evidence of P2Y12 Inhibitor Monotherapy**

Over the last years, several large-scale RCTs have assessed the safety and efficacy of aspirin-free antiplatelet strategies after coronary stenting (Figure 2 and Table 1). Two main approaches have been assessed: (a) trials comparing P2Y12 monotherapy versus conventional DAPT regimens after PCI and (b) trials comparing P2Y12 inhibitors vs aspirin monotherapy for long-term secondary prevention.

**Figure 2.** Randomized controlled trials of P2Y12 inhibitor monotherapy in patients treated with PCI. ASA, aspirin; DAPT, dual antiplatelet therapy; DAPT-C, clopidogrel-based dual antiplatelet therapy; DAPT-T, ticagrelor-based dual antiplatelet therapy; Invest., investigational group; PCI, percutaneous coronary intervention. \* In HOST-EXAM trial, event-free patients who maintained DAPT for 6–18 months after PCI were randomized.

**Table 1.** Randomized controlled trials for P2Y12 inhibitor monotherapy in patients treated with PCI.


\* Complete details about regimen duration are shown in Figure 1. ACS, acute coronary syndrome; ASA, aspirin; CAD, coronary artery disease; CCS, chronic coronary syndrome; CI, confidence interval; CV, cardiovascular; DAPT, dual antiplatelet therapy; HR, hazard ratio; PCI, percutaneous coronary intervention; PFT, platelet function test; RCT, randomized controlled trial; RR, rate ratio; TIMI, Thrombolysis in Myocardial Infarction.
